A Phase 2 interventional study of BMS-986012 and Carboplatin in Extensive-stage Small Cell Lung Cancer, sponsored by Bristol-Myers Squibb. Completed at 39 sites in 11 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-06-17.
Sponsored by Bristol-Myers Squibb · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 36 studies testing carboplatin in Small Cell Lung Carcinoma — 6 open to participants now, 9 under way, 1 of them phase 3. Carboplatin · Small Cell Lung Carcinoma.
Among the 36 studies testing carboplatin in Small Cell Lung Carcinoma, this one is the 5th largest by enrollment, is one of 5 that started in 2021, is one of 22 in phase 2, and was the 25th registered.
1,301 studies on the registry are indexed under Small Cell Lung Carcinoma; 365 are open to participants now.
Browse Small Cell Lung Carcinoma studies →6 of the 36 studies testing carboplatin in Small Cell Lung Carcinoma are open now, in 12 countries. Recruiting first, the newest first:
Boehringer Ingelheim · Sites in United States, Argentina, Australia and 39 more countries
Ages 18+
Sehhoon Park · Sites in Korea, Republic of
Ages 19+
Anhui Provincial Cancer Hospital · Sites in China
Ages 18+
Fox Chase Cancer Center · Sites in United States
Ages 18+
Fujian Cancer Hospital · Sites in China
Ages 18–75
By country, each count listing its studies:
Carboplatin: first FDA approval 1989 (PARAPLATIN). What it is approved for, and how studies give it, is on its page →
Of the 265 Small Cell Lung Carcinoma studies recruiting now, 175 (66%) set no upper age limit and 66 (25%) stop at 75 or younger; 3 take children under 18; 8 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
36 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 10 · Phase 2 26 · Phase 3 4
First in 1998; this study’s year is marked. 5 started in 2021.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 135 is above the median of 56 across 1,077 interventional studies indexed under Small Cell Lung Carcinoma.
Median enrollment 48 across the 36 interventional studies. Of the 22 that completed or were terminated, 10 (45%) have results posted.
This tab as a report to print or save as PDF → With an account.
11 of 36 have an industry lead sponsor. The 10 most frequent:
Bristol-Myers Squibb is the lead sponsor of 1,561 studies on the registry; 118 are open to participants now.
Of its 436 completed or terminated interventional studies of FDA-regulated products, 228 (52%) have results posted.
19 studies in Small Cell Lung Carcinoma by Bristol-Myers Squibb: 2 open now, 2 under way, 1 of them phase 3. Of 17 finished, 5 (29%) have results posted.
Among the 19 studies in Small Cell Lung Carcinoma by Bristol-Myers Squibb, this one is the 6th largest by enrollment of the 17 interventional ones that give a count, is the only one that started in 2021, is one of 6 in phase 2, and was the 16th registered.
Bristol-Myers Squibb’s Small Cell Lung Carcinoma studies by the year they started, since 2006.
4 of the studies testing carboplatin in Small Cell Lung Carcinoma that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT05856695Intergroupe Francophone de Cancerologie ThoraciqueDurvalumab Plus Etoposide-free Chemotherapy in First-line Treatment of Extensive-disease Small-sell Lung Cancer (SCLC) | 2026-11 |
| NCT06838208Anhui Provincial Cancer HospitalTislelizumab Combined With Chemotherapy and Relayed Radiotherapy in First-line Treatment of ES-SCLC | 2027-03-01 |
| NCT06830694Sehhoon ParkClinical Trial for Safety and Effectiveness Evaluation of Tarlatamab (AMG757) With Etoposide, Carboplatin and Atezolizumab in Transformed Small Cell Lung Cancer Patients From Adenocarcinoma After EGFR TKI Treatment | 2027-03-31 |
| NCT06449209BioNTech SESafety, Preliminary Effectiveness of BNT327, an Investigational Therapy for Patients With Small-cell Lung Cancer in Combination With Chemotherapy | 2027-06 |
Add all 4 to your calendar (.ics) → With an account.
Among the 36 studies testing carboplatin in Small Cell Lung Carcinoma, from their registry updates:
Nothing recorded among them since 2026-09-25.
Among Bristol-Myers Squibb’s 19 in Small Cell Lung Carcinoma:
This tab as a report to print or save as PDF → With an account.
The purpose of this study is to demonstrate that treatment with BMS-986012 in combination with carboplatin, etoposide, and nivolumab will have acceptable safety and tolerability and will improve progression-free survival compared with carboplatin, etoposide, and nivolumab alone in newly diagnosed participants with extensive-stage small cell lung cancer (ES-SCLC).
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Other protocol-defined inclusion/exclusion criteria apply
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).
Your pathology report is the document that shows this.
A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.
Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.
The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.
The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.
“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.
Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.
Histologically or cytologically confirmed
The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).
Your pathology report is the document that shows this.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Biopsy and archival tissue
A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.
Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Metastases
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECOG performance status
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Measurable disease
The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.
The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
RECIST
The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.
“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Autoimmune disease
A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.
Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Biological: BMS-986012 · Drug: Carboplatin · Drug: Etoposide · Biological: Nivolumab
Drug: Carboplatin · Drug: Etoposide · Biological: Nivolumab
Specified dose on specified days
Also known as: Fucosyl-GM1 Antibody
Specified dose on specified days
Specified dose on specified days
Specified dose on specified days
Also known as: BMS-936558
Number of Participants With Adverse Events
An adverse event (AE) is defined as any new untoward medical occurrence or worsening of a pre-existing medical condition in a clinical investigation participant administered study treatment that does not necessarily have a causal relationship with this treatment.
Time frame: From first dose to 100 days post last dose, or primary cutoff date, whichever occurs first (Up to approximately 43 months)
Number of Participants With Serious Adverse Events
Serious Adverse Event (SAE) is defined as any untoward medical occurrence that, at any dose results in death, is life-threatening, and requires inpatient hospitalization or causes prolongation of existing hospitalization.
Time frame: From first dose to 100 days post last dose, or primary cutoff date, whichever occurs first (Up to approximately 43 months)
Number of Participants With Adverse Events Leading to Discontinuation
An adverse event (AE) is defined as any new untoward medical occurrence or worsening of a pre-existing medical condition in a clinical investigation participant administered study treatment that does not necessarily have a causal relationship with this treatment.
Time frame: From first dose to 100 days post last dose, or primary cutoff date, whichever occurs first (Up to approximately 43 months)
Number of Participants Who Died
Number of participants who died due to any cause.
Time frame: From first dose to primary cutoff date (Up to approximately 43 months)
Progression Free Survival (PFS) Per Blinded Independent Central Review (BICR)
PFS based on RECIST v1.1 is defined as the time from randomization to the date of the first documented tumor progression by BICR or death from any cause. Estimates are based on Kaplan-Meier product-limit method. Progressive disease=At least a 20% increase in the sum of diameters of target lesions.
Time frame: From randomization to the date of the first documented tumor progression, or death, or primary cutoff date, whichever occurs first (Up to approximately 50 months)
Progression Free Survival Rate (PFSR) at 6 and 12 Months
PFSR is defined as the percentage of participants progression free at 6 and 12 months. PFS based on RECIST v1.1 is defined as the time from randomization to the date of the first documented tumor progression by Blinded Independent Central Review (BICR) and by investigator, or death from any cause. Progressive disease=At least a 20% increase in the sum of diameters of target lesions.
Time frame: 6 and 12 months
Progression Free Survival (PFS) Per Investigator
PFS based on RECIST v1.1 is defined as the time from randomization to the date of the first documented tumor progression by Investigator or death from any cause. Estimates are based on Kaplan-Meier product-limit method. Progressive disease=At least a 20% increase in the sum of diameters of target lesions.
Time frame: From randomization to the date of the first documented tumor progression, or death, whichever occurs first (Up to approximately 56 months)
Objective Response Rate (ORR)
ORR per Blinded Independent Central Review (BICR) and per investigator is defined as the percentage of participants with a confirmed best overall response of complete response (CR) or partial response (PR) by Response Evaluation Criteria in Solid Tumors (RECIST) v1.1. CR=Disappearance of all target lesions. PR=At least 30% decrease in the sum of diameters of target lesions.
Time frame: From randomization to the date of first documented response (Up to approximately 56 months)
Duration of Response (DoR)
DoR per Blinded Independent Central Review and per investigator is defined for participants who have a confirmed CR or PR as the date from first documented CR or PR per RECIST v1.1 to the date of the documentation of disease progression or death due to any cause, whichever is earlier. CR=Disappearance of all target lesions. PR=At least 30% decrease in the sum of diameters of target lesions.
Time frame: From randomization to the date of the documentation of disease progression or death due to any cause, whichever is earlier (Up to approximately 56 months)
Time to Response (TTR)
TTR per Blinded Independent Central Review (BICR) and per investigator is defined for participants who had a confirmed CR or PR as the time from the date of randomization to date of first documented CR or PR per RECIST v1.1. CR=Disappearance of all target lesions. PR=At least 30% decrease in the sum of diameters of target lesions.
Time frame: From randomization to the date of first documented CR or PR (Up to approximately 56 months)
Overall Survival (OS)
OS is defined as the time from randomization to the time of death due to any cause. OS will be estimated using the Kaplan-Meier method.
Time frame: From randomization to the date of death due to any cause (Up to approximately 56 months)
Overall Survival Rate (OSR) at 12 and 24 Months
OSR is defined as the percentage of participants surviving at 12 and 24 months. OS is defined as the time from randomization to the time of death due to any cause. OS will be estimated using the Kaplan-Meier method.
Time frame: 12 and 24 months
Number of Participants With Anti-Nivolumab Antibody (ADA)
ADA Positive: A participant with at least one ADA-positive sample relative to baseline (ADA negative at baseline or ADA titer to be at least 4-fold or greater (\>=) than baseline positive titer) at any time after initiation of treatment. Baseline ADA Positive: A participant with baseline ADA-positive sample.
Time frame: From baseline up to approximately 56 months
| Milestone | Arm A | Arm B |
|---|---|---|
| Started | 67 | 68 |
| Completed | 66 | 65 |
| Not completed | 1 | 3 |
| Withdrew: Participant request to discontinue study treatment | 0 | 1 |
| Withdrew: Withdrawal by subject | 0 | 1 |
| Withdrew: Participant no longer meets study criteria | 1 | 0 |
| Withdrew: Other reasons | 0 | 1 |
| Milestone | Arm A | Arm B |
|---|---|---|
| Started | 66 | 65 |
| Completed | 56 | 53 |
| Not completed | 10 | 12 |
| Withdrew: Participant request to discontinue study | 1 | 0 |
| Withdrew: Withdrawal by subject | 0 | 1 |
| Withdrew: Death | 1 | 0 |
| Withdrew: Disease progression | 2 | 3 |
| Withdrew: Study drug toxicity | 3 | 6 |
| Withdrew: Adverse event unrelated to study drug | 3 | 2 |
| Milestone | Arm A | Arm B |
|---|---|---|
| Started | 56 | 52 |
| Did not enter maintenance phase | 0 | 1 |
| Completed | 6 | 2 |
| Not completed | 50 | 50 |
| Withdrew: Withdrawal by subject | 0 | 1 |
| Withdrew: Death | 1 | 0 |
| Withdrew: Disease progression | 42 | 42 |
| Withdrew: Study drug toxicity | 1 | 4 |
| Withdrew: Adverse event unrelated to study drug | 2 | 0 |
| Withdrew: Other reasons | 1 | 1 |
| Withdrew: Participant request to discontinue study | 2 | 1 |
| Withdrew: Transitioned to rollover study | 1 | 1 |
PFSR is defined as the percentage of participants progression free at 6 and 12 months. PFS based on RECIST v1.1 is defined as the time from randomization to the date of the first documented tumor progression by Blinded Independent Central Review (BICR) and by investigator, or death from any cause. Progressive disease=At least a 20% increase in the sum of diameters of target lesions.
| Percentage of participants | Arm A | Arm B |
|---|---|---|
| 6 months - BICR | 48.7 (35.6 to 60.6) | 43.1 (30.0 to 55.5) |
| 6 months - Investigator | 56.4 (43.1 to 67.7) | 42.8 (30.1 to 55.0) |
| 12 months - BICR | 21.0 (11.4 to 32.5) | 22.2 (12.2 to 34.0) |
| 12 months Investigator | 18.1 (9.6 to 28.7) | 19.6 (10.6 to 30.8) |
PFS based on RECIST v1.1 is defined as the time from randomization to the date of the first documented tumor progression by Investigator or death from any cause. Estimates are based on Kaplan-Meier product-limit method. Progressive disease=At least a 20% increase in the sum of diameters of target lesions.
| Months | Arm A | Arm B |
|---|---|---|
| Progression Free Survival (PFS) Per Investigator | 6.47 (5.13 to 7.89) | 5.09 (4.76 to 6.67) |
ORR per Blinded Independent Central Review (BICR) and per investigator is defined as the percentage of participants with a confirmed best overall response of complete response (CR) or partial response (PR) by Response Evaluation Criteria in Solid Tumors (RECIST) v1.1. CR=Disappearance of all target lesions. PR=At least 30% decrease in the sum of diameters of target lesions.
| Percentage of participants | Arm A | Arm B |
|---|---|---|
| Per BICR | 73.1 (60.9 to 83.2) | 66.2 (53.7 to 77.2) |
| Per Investigator | 74.6 (62.5 to 84.5) | 61.8 (49.2 to 73.3) |
DoR per Blinded Independent Central Review and per investigator is defined for participants who have a confirmed CR or PR as the date from first documented CR or PR per RECIST v1.1 to the date of the documentation of disease progression or death due to any cause, whichever is earlier. CR=Disappearance of all target lesions. PR=At least 30% decrease in the sum of diameters of target lesions.
| Months | Arm A | Arm B |
|---|---|---|
| per BICR | 6.41 (4.30 to 7.39) | 4.50 (3.48 to 5.49) |
| per Investigator | 5.29 (4.73 to 6.87) | 4.96 (3.48 to 6.70) |
TTR per Blinded Independent Central Review (BICR) and per investigator is defined for participants who had a confirmed CR or PR as the time from the date of randomization to date of first documented CR or PR per RECIST v1.1. CR=Disappearance of all target lesions. PR=At least 30% decrease in the sum of diameters of target lesions.
| Months | Arm A | Arm B |
|---|---|---|
| per BICR | 1.51 (1.3 to 3.0) | 1.58 (1.2 to 5.2) |
| per Investigator | 1.51 (1.2 to 5.0) | 1.63 (1.2 to 18.1) |
An adverse event (AE) is defined as any new untoward medical occurrence or worsening of a pre-existing medical condition in a clinical investigation participant administered study treatment that does not necessarily have a causal relationship with this treatment.
| Participants | Arm A | Arm B |
|---|---|---|
| Number of Participants With Adverse Events | 66 | 65 |
Serious Adverse Event (SAE) is defined as any untoward medical occurrence that, at any dose results in death, is life-threatening, and requires inpatient hospitalization or causes prolongation of existing hospitalization.
| Participants | Arm A | Arm B |
|---|---|---|
| Number of Participants With Serious Adverse Events | 38 | 34 |
An adverse event (AE) is defined as any new untoward medical occurrence or worsening of a pre-existing medical condition in a clinical investigation participant administered study treatment that does not necessarily have a causal relationship with this treatment.
| Participants | Arm A | Arm B |
|---|---|---|
| Number of Participants With Adverse Events Leading to Discontinuation | 13 | 16 |
Number of participants who died due to any cause.
| Participants | Arm A | Arm B |
|---|---|---|
| Number of Participants Who Died | 47 | 53 |
PFS based on RECIST v1.1 is defined as the time from randomization to the date of the first documented tumor progression by BICR or death from any cause. Estimates are based on Kaplan-Meier product-limit method. Progressive disease=At least a 20% increase in the sum of diameters of target lesions.
| Months | Arm A | Arm B |
|---|---|---|
| Progression Free Survival (PFS) Per Blinded Independent Central Review (BICR) | 5.78 (4.99 to 7.89) | 5.59 (4.86 to 6.57) |
OS is defined as the time from randomization to the time of death due to any cause. OS will be estimated using the Kaplan-Meier method.
| Months | Arm A | Arm B |
|---|---|---|
| Overall Survival (OS) | 16.26 (12.22 to 23.66) | 13.08 (9.72 to 16.62) |
OSR is defined as the percentage of participants surviving at 12 and 24 months. OS is defined as the time from randomization to the time of death due to any cause. OS will be estimated using the Kaplan-Meier method.
| Percentage of participants | Arm A | Arm B |
|---|---|---|
| 12 months | 64.7 (51.9 to 75.0) | 51.7 (38.8 to 63.0) |
| 24 months | 37.8 (26.1 to 49.5) | 25.0 (15.2 to 36.1) |
ADA Positive: A participant with at least one ADA-positive sample relative to baseline (ADA negative at baseline or ADA titer to be at least 4-fold or greater (\>=) than baseline positive titer) at any time after initiation of treatment. Baseline ADA Positive: A participant with baseline ADA-positive sample.
| Participants | Arm A |
|---|---|
| BMS-986012 ADA Positive | 2 |
| Nivolumab ADA Positive | 4 |
An adverse event (AE) is defined as any new untoward medical occurrence or worsening of a pre-existing medical condition in a clinical investigation participant administered study treatment that does not necessarily have a causal relationship with this treatment.
| Participants | Arm A | Arm B |
|---|---|---|
| Number of Participants With Adverse Events - Extended Collection | 66 | 65 |
Serious Adverse Event (SAE) is defined as any untoward medical occurrence that, at any dose results in death, is life-threatening, and requires inpatient hospitalization or causes prolongation of existing hospitalization.
| Participants | Arm A | Arm B |
|---|---|---|
| Number of Participants With Serious Adverse Events - Extended Collection | 38 | 34 |
An adverse event (AE) is defined as any new untoward medical occurrence or worsening of a pre-existing medical condition in a clinical investigation participant administered study treatment that does not necessarily have a causal relationship with this treatment.
| Participants | Arm A | Arm B |
|---|---|---|
| Number of Participants With Adverse Events Leading to Discontinuation - Extended Collection | 13 | 15 |
Number of participants who died due to any cause.
| Participants | Arm A | Arm B |
|---|---|---|
| Number of Participants Who Died - Extended Collection | 50 | 56 |
PFS based on RECIST v1.1 is defined as the time from randomization to the date of the first documented tumor progression by BICR or death from any cause. Estimates are based on Kaplan-Meier product-limit method. Progressive disease=At least a 20% increase in the sum of diameters of target lesions.
| Months | Arm A | Arm B |
|---|---|---|
| Progression Free Survival (PFS) Per Blinded Independent Central Review (BICR) - Extended Collection | 5.78 (4.99 to 7.89) | 5.59 (4.86 to 6.57) |
Collected over All-Cause Mortality (ACM) was assessed from randomization until their study completion (Up to approximately 56 months). Adverse Events (AEs) and Serious Adverse (SAEs) were assessed from first dose to 100 days post last dose (Up to approximately 47 months). Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Arm A | 50/67 (74.6%) | 38/66 (57.6%) | 62/66 (93.9%) |
| Arm B | 56/68 (82.4%) | 34/65 (52.3%) | 62/65 (95.4%) |
| Event | Arm A | Arm B |
|---|---|---|
| Malignant neoplasm progressionNeoplasms benign, malignant and unspecified (incl cysts and polyps) | 6/66 | 3/65 |
| Febrile neutropeniaBlood and lymphatic system disorders | 3/66 | 5/65 |
| PneumoniaInfections and infestations | 4/66 | 4/65 |
| Septic shockInfections and infestations | 0/66 | 3/65 |
| ThrombocytopeniaBlood and lymphatic system disorders | 0/66 | 2/65 |
| SepsisInfections and infestations | 2/66 | 2/65 |
| Respiratory failureRespiratory, thoracic and mediastinal disorders | 0/66 | 2/65 |
| Cardio-respiratory arrestCardiac disorders | 2/66 | 1/65 |
| COVID-19Infections and infestations | 2/66 | 0/65 |
| Clostridium difficile colitisInfections and infestations | 2/66 | 0/65 |
| Event | Arm A | Arm B |
|---|---|---|
| PruritusSkin and subcutaneous tissue disorders | 41/66 | 12/65 |
| AnaemiaBlood and lymphatic system disorders | 26/66 | 39/65 |
| NauseaGastrointestinal disorders | 19/66 | 23/65 |
| NeutropeniaBlood and lymphatic system disorders | 22/66 | 21/65 |
| ThrombocytopeniaBlood and lymphatic system disorders | 22/66 | 21/65 |
| AlopeciaSkin and subcutaneous tissue disorders | 20/66 | 18/65 |
| DiarrhoeaGastrointestinal disorders | 18/66 | 12/65 |
| FatigueGeneral disorders and administration site conditions | 17/66 | 10/65 |
| Decreased appetiteMetabolism and nutrition disorders | 13/66 | 16/65 |
| ConstipationGastrointestinal disorders | 15/66 | 15/65 |
| Age, Continuous(Years) | Arm A | Arm B | Total |
|---|---|---|---|
| Mean | 66.0 ± 7.29 | 66.0 ± 8.37 | 66.0 ± 7.82 |
| Sex: Female, Male(Participants) | Arm A | Arm B | Total |
|---|---|---|---|
| Female | 24 | 35 | 59 |
| Male | 43 | 33 | 76 |
| Ethnicity (NIH/OMB)(Participants) | Arm A | Arm B | Total |
|---|---|---|---|
| Hispanic or Latino | 1 | 1 | 2 |
| Not Hispanic or Latino | 41 | 47 | 88 |
| Unknown or Not Reported | 25 | 20 | 45 |
| Race (NIH/OMB)(Participants) | Arm A | Arm B | Total |
|---|---|---|---|
| American Indian or Alaska Native | 0 | 0 | 0 |
| Asian | 4 | 6 | 10 |
| Native Hawaiian or Other Pacific Islander | 0 | 0 | 0 |
| Black or African American | 1 | 0 | 1 |
| White | 60 | 62 | 122 |
| More than one race | 0 | 0 | 0 |
| Unknown or Not Reported | 2 | 0 | 2 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: Yes — BMS will provide access to individual anonymized participant data upon request from qualified researchers, and subject to certain criteria. Additional information regarding Bristol Myer Squibb's data sharing policy and process can be found at https://www.bms.com/researchers-and-partners/clinical-trials-and-research.html
Supporting information: Study protocol, Statistical analysis plan, Clinical study report
Time frame: See Plan Description
Access criteria: See Plan Description
Data sharing details ↗ · www.bms.com
Ran from Mar 2021 to primary completion in May 2025, 50 months.
Results were first posted in Jun 2026, 1 year after primary completion.
Of 54 industry-sponsored phase 2 interventional studies under Small Cell Lung Carcinoma, half reached primary completion within 35 months of starting (the median), counting those still running; a quarter within 18 and three quarters within 44. This study's 50 months is above that.
Counting every sponsor, half of 204 studies reached it within 46 months; a quarter within 29 and three quarters within 84.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in May 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drugs tested here: Carboplatin · Etoposide